• 
• 
• 
• 
  • Ogłoszenia
  • Plan wydawniczy
  • Regulamin ogłaszania prac
  • Zasady recenzowania i recenzenci
• 
• 
• 
• 

Wydanie specjalne czerwiec 2015
str. 18

Konwersja terapii anty-VEGF wysiękowej postaci zwyrodnienia plamki związanego z wiekiem – doświadczenia własne

Switching anty-VEGF Therapy in Wet Age-related Macular Degeneration – Own Experience

Małgorzata Figurska

Klinika Okulistyki Wojskowego Instytutu Medycznego w Warszawie
Kierownik: prof. dr hab. n. med. Marek Rękas

Summary: Intravitreal anti-VEGF injections have been used in neovascular age-related macular degeneration treatment since the beginning of 21st century. Ranibizumab was the first non-selective drug registered in neovascular age-related macular degeneration treatment. Due to repetitive injections of ranibizumab in most cases the progression of the disease is stopped. Nevertheless, anti-vascular endothelial growth factor therapy is palliative and it does not lead to complete cure. Neovascularization activity continues for at least few years, therefore patients require consecutive injections of anti-vascular endothelial growth factors to maintain clinical and morphological remission achieved in the principal phase of the treatment. With time group of patients resistant to treatment to date evolves. One of the options in this setting is to switch to a similar drug with different properties – aflibercept (Eylea). This drug has been available in European Union countries since 2013 and it not only blocks vascular endothelial growth factor but also placental growth factor. The following paper presents clinical cases of conversion from ranibizumab or bevacizumab to aflibercept. The influence of aflibercept for refractory neovascular age-related macular degeneration on anatomical and functional outcomes was investigated based on optical coherence tomography and visual acuity.

Słowa kluczowe: zwyrodnienie plamki związane z wiekiem, postać wysiękowa zwyrodnienia plamki związanego z wiekiem, terapia ranibizumabem, afliberceptem, bewacyzumabem, konwersja terapii.

Keywords: age-related macular degeneration (AMD), wet age-related macular degeneration (wet AMD), ranibizumab, aflibercept, bevacizumab therapy, switching therapy.

powrót